UK-based AviadoBio has expanded its exclusive license agreement with King's College London, converting a neurology-only platform license into a universal IP position covering all human therapeutic areas — a structural move that repositions the gene therapy spinout as a potential platform licensor across cardiovascular, nephrology, and oncology. The deal expands AviadoBio's rights to the vMiX vectorized RNAi gene silencing technology, originally licensed from KCL in 2020, to encompass any human indication. Financial terms were not disclosed.
The expansion is structurally unusual: most academic platform license amendments are incremental, adding one or two adjacent indications. Expanding from a single disease area to all human therapeutic areas in a single amendment is rare, effectively converting a disease-specific license into a universal one. The announcement coincides with positive preclinical data for AVB-406, AviadoBio's Alzheimer's disease and tauopathy program, presented in three oral sessions at the American Society of Gene & Cell Therapy annual meeting in May 2026, where dose-dependent MAPT knockdown of up to 80% in the brain was reported.
Deal context
The vMiX platform uses AAV as a delivery vehicle to encode artificial microRNA sequences that harness the cell's endogenous RNAi machinery, producing durable gene silencing from a single administration. The platform can silence up to three genes simultaneously and supports knockdown-and-replace strategies via inclusion of a transgene. Cell-type-specific promoters restrict silencing activity to regions of disease pathology. Described by AviadoBio as enabling "one-time, durable gene silencing," the platform's key differentiation from systemic siRNA approaches — including GalNAc-siRNA used by Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals — is persistence: AAV episomes in post-mitotic cells can produce sustained silencing without repeat dosing.
The lead program built on the platform is AVB-101, an AAV gene therapy for frontotemporal dementia with GRN mutations, which AviadoBio licensed to Astellas Pharma in October 2024 in a deal structured as an exclusive option and license. Under that agreement, Astellas paid a USD 20 million equity investment plus up to USD 30 million in upfront option payments, with AviadoBio eligible for up to USD 2.18 billion in license fees and milestones plus royalties upon option exercise. The KCL license expansion is the upstream IP consolidation that enables AviadoBio to replicate that structure in new therapeutic areas with future pharma partners.